1,077 results

#172922-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-jGCaMP8m-P2A-mRuby3 (#172922). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-jGCaMP8m-P2A-mRuby3 plasmid DNA. hSyn-driven expression of jGCaMP8m in axons with cytosolic expression of mRuby3. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aug. 24, 2023

Academic Institutions and Nonprofits only

#28306-AAV8

Ready-to-use AAV8 particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Oct. 18, 2021

Academic Institutions and Nonprofits only

#117382-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#159605-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-NIR-GECO2G (#159605). In addition to the viral particles, you will also receive purified pAAV-CAG-NIR-GECO2G plasmid DNA. CAG-driven expression of the near-infrared calcium indicator NIR-GECO2G. These AAV preparations are suitable purity for injection into animals.

Robert Campbell

Qian et al PLoS Biol. 2020 Nov 24;18(11):e3000965.

Dec. 18, 2024

Academic Institutions and Nonprofits only

#137122-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-Con/Fon-GCaMP6F (#137122). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-GCaMP6F plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

July 17, 2020

Academic Institutions and Nonprofits only

#101060-AAV1

Ready-to-use AAV1 particles produced from pAAV_hsyn_NES-his-CaMPARI2-WPRE-SV40 (#101060). In addition to the viral particles, you will also receive purified pAAV_hsyn_NES-his-CaMPARI2-WPRE-SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator his-tagged CaMPARI2. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Moeyaert et al Nat Commun. 2018 Oct 25;9(1):4440. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#114469-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa-mCherry (#114469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mCherry plasmid DNA. CamKIIa-driven expression of mCherry. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 16, 2020

Academic Institutions and Nonprofits only

#232351-AAV5

Ready-to-use AAV5 particles produced from pAAV-ATLASsnCre (#232351). In addition to the viral particles, you will also receive purified pAAV-ATLASsnCre plasmid DNA. Syn-driven, ATLASsnCre expression. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Rivera et al Nat Methods. 2025 May;22(5):1101-1111. d

Sept. 22, 2025

Academic Institutions and Nonprofits only

#213943-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#214147-AAV5

Ready-to-use AAV5 particles produced from pAAV-hIBA1a-GFP-miR124T (#214147). In addition to the viral particles, you will also receive purified pAAV-hIBA1a-GFP-miR124T plasmid DNA. hIBA1a-driven and miR124T-targeted for microglial inhibition of GFP. These AAV preparations are suitable purity for injection into animals.

Chun-Li Zhang

Serrano et al iScience. 2024 Aug 12;27(9):110706. doi:

Sept. 22, 2025

Academic Institutions and Nonprofits only